Tagraxofusp联合阿扎胞苷±维奈克拉治疗急性髓系白血病的1b期试验
这项1b期研究纳入56例CD123阳性急性髓系白血病或高危骨髓增生异常综合征成人患者,先评估Tagraxofusp联合阿扎胞苷,后评估三药联合维奈克拉。Tagraxofusp推荐2期剂量为12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。在26例初治欧洲白血病网不良风险急性髓系白血病扩展队列中,三药联合诱导缓解率69%,中位总生存14个月。
要点
- Tagraxofusp联合阿扎胞苷±维奈克拉在CD123阳性急性髓系白血病中显示可控的安全性。
- 推荐2期剂量为Tagraxofusp 12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。
- 三药联合在初治不良风险急性髓系白血病中诱导缓解率69%,支持进一步临床开发。
核心结论
- Tagraxofusp联合阿扎胞苷和维奈克拉在高危急性髓系白血病(包括TP53突变疾病)中显示出令人鼓舞的安全性和活性,支持Tagraxofusp联合方案的进一步临床开发。
研究设计与样本
- 1b期研究纳入56例CD123阳性急性髓系白血病或高危骨髓增生异常综合征成人患者,先评估Tagraxofusp联合阿扎胞苷,后评估Tagraxofusp、阿扎胞苷和维奈克拉三药联合。
- 研究注册于ClinicalTrials.gov,编号NCT03113643。
主要发现
- 3天Tagraxofusp给药的不良事件符合预期,未提示Tagraxofusp或阿扎胞苷±维奈克拉联合时毒性增加。
- Tagraxofusp推荐2期剂量为12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。
- 在26例初治欧洲白血病网不良风险急性髓系白血病扩展队列(中位年龄71岁,50% TP53突变)中,三药联合诱导缓解率69%(n=18/26;完全缓解39%,伴计数不完全恢复的完全缓解19%,形态学无白血病状态12%)。
- 13例TP53突变患者中,7/13(54%)达到完全缓解/伴计数不完全恢复的完全缓解/形态学无白血病状态(完全缓解=4,伴计数不完全恢复的完全缓解=2,形态学无白血病状态=1)。
- 17例可检测缓解者中12例(71%)无流式可测量残留病;中位总生存14个月(95%CI,9.5-NA),中位无进展生存8.5个月(95%CI,5.1-NA)。
关键数值与推荐
- Tagraxofusp推荐2期剂量为12 μg/kg/天连用3天,联合7天阿扎胞苷±21天维奈克拉。
- 三药联合扩展队列诱导缓解率69%(n=18/26),其中完全缓解39%、伴计数不完全恢复的完全缓解19%、形态学无白血病状态12%。
- TP53突变患者中54%(7/13)达到完全缓解/伴计数不完全恢复的完全缓解/形态学无白血病状态(完全缓解=4,伴计数不完全恢复的完全缓解=2,形态学无白血病状态=1)。
- 可检测缓解者中71%(12/17)无流式可测量残留病。
- 中位总生存14个月(95%CI,9.5-NA),中位无进展生存8.5个月(95%CI,5.1-NA)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD123, a subunit of the interleukin-3 receptor, is expressed on ∼80% of acute myeloid leukemias (AMLs). Tagraxofusp (TAG), recombinant interleukin-3 fused to a truncated diphtheria toxin payload, is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm. We previously found that AMLs with acquired resistance to TAG were re-sensitized by the DNA hypomethylating agent azacitidine (AZA) and that TAG-exposed cells became more dependent on the antiapoptotic molecule BCL-2. Here, we report a phase 1b study in 56 adults with CD123-positive AML or high-risk myelodysplastic syndrome (MDS), first combining TAG with AZA in AML/MDS, and subsequently TAG, AZA, and the BCL-2 inhibitor venetoclax (VEN) in AML. Adverse events with 3-day TAG dosing were as expected, without indication of increased toxicity of TAG or AZA+/-VEN in combination. The recommended phase 2 dose of TAG was 12 μg/kg/day for 3 days, with 7-day AZA +/- 21-day VEN. In an expansion cohort of 26 patients (median age 71) with previously untreated European LeukemiaNet adverse-risk AML (50% TP53 mutated), triplet TAG-AZA-VEN induced response in 69% (n=18/26; 39% complete remission [CR], 19% complete remission with incomplete count recovery [CRi], 12% morphologic leukemia-free state [MLFS]). Among 13 patients with TP53 mutations, 7/13 (54%) achieved CR/CRi/MLFS (CR = 4, CRi = 2, MLFS = 1). Twelve of 17 (71%) tested responders had no flow measurable residual disease. Median overall survival and progression-free survival were 14 months (95% CI, 9.5-NA) and 8.5 months (95% CI, 5.1-NA), respectively. In summary, TAG-AZA-VEN shows encouraging safety and activity in high-risk AML, including TP53-mutated disease, supporting further clinical development of TAG combinations. The study was registered on ClinicalTrials.gov as #NCT03113643.
引用
- Lane AA, Garcia JS, Raulston EG, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024. PMID: 38052038. doi:10.1182/bloodadvances.2023011721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。